Kimimori Kamijo

Kobe, 6500047, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Absence of Pretransplant Peripheral Blasts Is a Favorable Factor in Allogeneic Stem Cell Transplantation for Advanced Acute Lymphoblastic Leukemia.

Absence of Pretransplant Peripheral Blasts Is a Favorable Factor in Allogeneic Stem Cell Transplantation for Advanced Acute Lymphoblastic Leukemia.

Journal: Transplantation and cellular therapy

Published: February 22, 2026

Efficacy of Low-Dose Olanzapine for the Prevention of Conditioning Therapy-Induced Nausea and Vomiting in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Efficacy of Low-Dose Olanzapine for the Prevention of Conditioning Therapy-Induced Nausea and Vomiting in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: August 08, 2025

Non-germinal center diffuse large B-cell lymphoma arising from a common origin of duodenal-type follicular lymphoma.

Non-germinal center diffuse large B-cell lymphoma arising from a common origin of duodenal-type follicular lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: April 29, 2025

Successful remission induction with reduced-dose all-trans retinoic acid for acute promyelocytic leukemia complicated by COVID-19

Successful remission induction with reduced-dose all-trans retinoic acid for acute promyelocytic leukemia complicated by COVID-19

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 03, 2024

Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation.

Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation.

Journal: British journal of haematology

Published: April 12, 2024

Multiple microthromboses with autoimmune hemolytic anemia after BNT162b2 mRNA vaccination

Multiple microthromboses with autoimmune hemolytic anemia after BNT162b2 mRNA vaccination

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: December 10, 2023

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation.

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation.

Journal: Cell transplantation

Published: August 30, 2023

Tumor lysis syndrome followed by tumor regression after COVID-19 in a patient with chronic lymphocytic leukemia.

Tumor lysis syndrome followed by tumor regression after COVID-19 in a patient with chronic lymphocytic leukemia.

Journal: International cancer conference journal

Published: June 16, 2023

An elderly patient with lymphoplasmacytic lymphoma successfully treated with low-dose tirabrutinib

An elderly patient with lymphoplasmacytic lymphoma successfully treated with low-dose tirabrutinib

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: April 30, 2023

Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.

Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.

Journal: International journal of hematology

Published: April 02, 2023

Trajectories of the SARS-CoV-2 RNA load in patients with hematological malignancy.

Trajectories of the SARS-CoV-2 RNA load in patients with hematological malignancy.

Journal: European journal of haematology

Published: January 11, 2023

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies.

Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies.

Journal: Blood cancer journal

Published: November 30, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026